伴与不伴骨髓增殖性肿瘤的内脏静脉血栓形成比较队列研究
该多中心比较队列研究纳入1189例内脏静脉血栓形成(SVT)患者(187例伴骨髓增殖性肿瘤MPN),评估抗凝管理及6个月复发血栓、出血和生存结局。结果显示,伴与不伴MPN患者抗凝启动与维持比例相似,6个月累积复发血栓发生率2.5%、出血4.5%、总生存率93.7%。倾向评分加权及亚组分析均未发现两组临床结局存在显著差异。
要点
- SVT患者中伴与不伴MPN者6个月复发血栓、出血及生存结局无显著差异。
- 76.1%患者在SVT诊断后30天内启动抗凝,78.6%在6个月时仍维持抗凝。
- MPN相关SVT在抗凝管理和结局上可参照非肝硬化非恶性SVT处理。
核心结论
- 伴与不伴MPN的SVT患者6个月内复发血栓、出血和生存结局相似。
- MPN相关SVT可视为与非肝硬化、非恶性SVT类似进行抗凝管理。
研究设计与样本
- 多中心比较队列研究,使用3项已发表研究和2个医院队列的个体患者数据。
- 纳入1189例成人SVT患者,其中187例伴潜在MPN。
- 采用倾向评分加权比较伴与不伴MPN患者的结局,并排除肝硬化或实体癌患者进行亚组分析。
主要发现
- 76.1%患者在SVT诊断后30天内启动抗凝,78.6%在6个月时仍接受抗凝,伴与不伴MPN者相似。
- 6个月累积复发血栓发生率为2.5%,出血发生率为4.5%。
- 6个月随访总生存率为93.7%。
- 伴与不伴MPN患者临床结局无显著差异,亚组分析亦证实。
关键数值与推荐
- SVT诊断后30天内抗凝启动比例76.1%。
- 6个月时仍抗凝比例78.6%。
- 6个月累积复发血栓发生率2.5%,出血发生率4.5%。
- 6个月总生存率93.7%。
临床怎么用
- MPN相关SVT患者的抗凝管理可参照非肝硬化、非恶性SVT的处理策略。
- 需关注SVT患者6个月内的复发血栓和出血风险,伴或不伴MPN均应密切监测。
局限性
- MPN相关SVT患者仍需前瞻性长期随访研究。
- 本研究为回顾性队列分析,使用已发表研究和医院队列的个体数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Splanchnic vein thrombosis (SVT) is a rare type of venous thromboembolism but relatively common in patients with myeloproliferative neoplasms (MPNs). Studies on management and outcomes for patients with MPN-SVT, including comparisons with non-MPN-SVT, are scarce. OBJECTIVES: We assessed anticoagulant management and recurrent thrombosis, bleeding, and survival outcomes in SVT patients with and without MPN. METHODS: We conducted a multicenter comparative cohort study in adults with SVT using individual patient data from 3 published studies and 2 hospital cohorts. Anticoagulant management after SVT diagnosis was evaluated; 6-month cumulative incidences of recurrent thrombosis, bleeding, and death were calculated. We used propensity score weighting to compare outcomes between patients with and without MPN. A subanalysis excluding patients with cirrhosis or solid cancer was performed. RESULTS: We investigated 1189 patients with SVT, 187 with underlying MPN. Anticoagulation was started in 76.1% of patients within 30 days after SVT diagnosis, 78.6% were still anticoagulated at 6 months; this was similar between patients with and without MPN. The 6-month cumulative incidence of recurrent thrombosis and bleeding was 2.5% and 4.5%, respectively. Overall survival was 93.7% at the 6-month follow-up. No significant differences were observed in clinical outcomes between patients with and without MPN, also confirmed by subanalyses. CONCLUSION: In this large cohort, incidences of recurrent thrombosis, bleeding and survival 6 months after SVT were similar in patients with and without MPN. This suggests that MPN-related SVT could be regarded similarly to noncirrhotic, nonmalignant SVT for anticoagulant management and outcomes. Prospective studies with long-term follow-up are still needed for MPN-related patients with SVT.
引用
- Ko AK, Milana L, Riva N, et al. Splanchnic vein thrombosis with and without myeloproliferative neoplasms: a comparative cohort study. J Thromb Haemost. 2026. PMID: 42173290. doi:10.1016/j.jtha.2026.05.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。